Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.22016153942205954 | N/A |
Market Cap | $13.31M | N/A |
Shares Outstanding | 60.46M | 21.50% |
Employees | 0 | N/A |
Shareholder Equity | 21.88M | -13.64% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -3.19 | N/A |
P/S Ratio | 6585.09 | N/A |
P/B Ratio | 0.61 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.1254 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $2.02K | N/A |
Earnings | -$2.74M | N/A |
EPS | -0.069 | N/A |
Earnings Yield | -0.3134 | N/A |
Gross Margin | 1.00 | N/A |
Operating Margin | -1.87K | N/A |
Net income margin | -1.36K | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $14.71M | N/A |
Cash on Hand | $14.06M | N/A |
Debt to Equity | 0.0149 | 2.91% |
Current Ratio | $45.59 | -1.62% |